芬兰五年轮状病毒疫苗接种的影响及二级医疗保健相关成本节约
本研究评估芬兰2009年启动的国家轮状病毒疫苗接种规划在最初五年对五岁以下儿童医院治疗的急性胃肠炎和严重轮状病毒疾病负担的影响,并评价二级医疗保健成本节约。2014年所有五岁以下儿童均符合接种条件时,医院治疗的轮状病毒胃肠炎发病率下降92.9%(95%CI:91.0%-94.5%),医院治疗的急性胃肠炎总发病率下降68.5%(66.6%-70.3%)。
要点
- 2014年五岁以下儿童医院治疗的轮状病毒胃肠炎发病率下降92.9%(95%CI:91.0%-94.5%)。
- 医院治疗的急性胃肠炎总发病率下降68.5%(66.6%-70.3%),医院门诊急性胃肠炎发病率增加6.3%(2.7%-9.9%)。
- 规划每年净节约二级医疗保健成本220万欧元,即每名接种儿童33欧元。
核心结论
- 轮状病毒疫苗接种规划明确控制了严重的、需医院治疗的轮状病毒胃肠炎。
- 轮状病毒疫苗接种规划每年至少在二级医疗保健成本上收回自身费用两倍以上。
研究设计与样本
- 基于芬兰医疗保健登记册中记录的ICD10诊断编码,比较规划启动前(1999-2005年)与启动后(2010-2014年)五岁以下儿童医院住院和医院门诊的急性胃肠炎(A00-A09,R11)及轮状病毒胃肠炎(A08.0)发病率。
主要发现
- 2014年五岁以下儿童医院住院轮状病毒胃肠炎发病率下降92.9%(95%CI:91.0%-94.5%),医院住院急性胃肠炎总发病率下降68.5%(66.6%-70.3%)。
- 医院门诊轮状病毒胃肠炎发病率下降91.4%(82.4%-96.6%),医院门诊急性胃肠炎发病率增加6.3%(2.7%-9.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to estimate the impact of the national rotavirus (RV) vaccination programme, starting 2009, on the total hospital-treated acute gastroenteritis (AGE) and severe RV disease burden in Finland during the first five years of the programme. This study also evaluated the costs saved in secondary healthcare by the RV vaccination programme. METHODS: The RV related outcome definitions were based on ICD10 diagnostic codes recorded in the Care Register for Health Care. Incidences of hospitalised and hospital outpatient cases of AGE (A00-A09, R11) and RVGE (A08.0) were compared prior (1999-2005) and after (2010-2014) the start of the programme among children less than five years of age. RESULTS: The reduction in disease burden in 2014, when all children under five years of age have been eligible for RV vaccination, was 92.9% (95%CI: 91.0%-94.5%) in hospitalised RVGE and 68.5% (66.6%-70.3%) in the total hospitalised AGE among children less than five years of age. For the corresponding hospital outpatient cases, there was a reduction of 91.4% (82.4%-96.6%) in the RVGE incidence, but an increase of 6.3% (2.7%-9.9%) in the AGE incidence. The RV vaccination programme prevented 2206 secondary healthcare AGE cases costing €4.5 million annually. As the RV immunisation costs were €2.3 million, the total net savings just in secondary healthcare costs were €2.2 million, i.e. €33 per vaccinated child. DISCUSSION: The RV vaccination programme clearly controlled the severe, hospital-treated forms of RVGE. The total disease burden is a more valuable end point than mere specifically diagnosed cases as laboratory confirmation practises usually change after vaccine introduction. The RV vaccination programme annually pays for itself at least two times over.
引用
- Leino T, Baum U, Scott P, et al. Impact of five years of rotavirus vaccination in Finland - And the associated cost savings in secondary healthcare. Vaccine. 2017. PMID: 28893475. doi:10.1016/j.vaccine.2017.08.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。